Xilio Therapeutics, Inc. Net Fee Amt
Xilio Therapeutics, Inc. (XLO) had Net Fee Amt of $471.51 as of 2026-08-11, per its S-8 filed 2026-08-12.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-12
- 2026-08-11: Net Fee Amt $471.51.
- 2026-05-27: Net Fee Amt $634.74.
- 2026-05-06: Net Fee Amt $33.15K.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-11 | $471.51 S-8 · filed 2026-08-12 |
| 2026-05-27 | $634.74 S-3/A · filed 2026-05-27 |
| 2026-05-06 | $33.15K S-3 · filed 2026-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |